Could a common food fiber boost immunotherapy in kidney cancer?
NCT ID NCT06866262
First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This study tests whether adding inulin gel, a fiber supplement, to standard immunotherapy drugs (ipilimumab and nivolumab) can help control advanced kidney cancer. About 55 adults with metastatic or locally advanced clear cell or sarcomatoid kidney cancer will take part. Researchers will check if the combination is safe and improves 6-month progression-free survival compared to immunotherapy alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- inulin gel (a dietary fiber) combined with ipilimumab and nivolumab (immunotherapy drugs)
- What this could lead to
- If it works, this could improve how well immunotherapy fights advanced kidney cancer by boosting gut bacteria.
- What could go wrong
- This is an early phase trial with only 55 people, so results may not apply widely. Inulin gel could cause digestive side effects or not enhance the drugs' effect.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Michigan Comprehensive Cancer Center
RECRUITINGAnn Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill rewrite the genetic story of resistant kidney cancer?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Old drug, new hope: mercaptopurine tested against rare cancer syndrome
- New imaging agent aims to spot Hard-to-Find kidney cancer spread
- Immunotherapy after kidney surgery may delay cancer return in rare kidney cancer